Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tolterodine: an overview.

J Wefer1, M C Truss, U Jonas

  • 1Department of Urology, Hannover Medical School, Germany. joerg.wefer@gmx.net

World Journal of Urology
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced Expression of the Cell Cycle Regulator p27<sup>Kip1</sup> within the Invasion Front of Renal Cell Carcinomas Proved to be a Significant Marker for Disease-specific Survival.

Cancer genomics & proteomics·2019
Same author

[Prostate biopsy. Update for indication, procedure, and future developments].

Der Urologe. Ausg. A·2014
Same author

Psychological distress and adjustment to disease in patients before and after radical prostatectomy. Results of a prospective multi-centre study.

European journal of cancer care·2014
Same author

[On the occasion of Prof. Dr. med. Dr. h.c. Jürgen B. Sökeland's 80th birthday].

Der Urologe. Ausg. A·2013
Same author

[Pathophysiology of fibrotic encapsulation of episcleral glaucoma drainage implants: modification for improvement of clinical results].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2013
Same author

[Small renal mass].

Der Urologe. Ausg. A·2012
Same journal

Holmium laser enucleation of the prostate as salvage therapy for benign prostatic obstruction after multiple prior surgical interventions.

World journal of urology·2026
Same journal

Testing reliability of pubourethral ligament hemostat forceps support test for diagnosis of stress incontinence.

World journal of urology·2026
Same journal

Safety and efficacy of different surgical approaches in single-port robot-assisted radical prostatectomy based on propensity score matching analysis.

World journal of urology·2026
Same journal

Intrarenal pressure and clinical outcomes during suction-assisted versus conventional percutaneous nephrolithotomy: a systematic review and meta-analysis.

World journal of urology·2026
Same journal

AI-driven model for early failure prediction after HIFU integrating immediate post-ablation ultrasound and clinical data.

World journal of urology·2026
Same journal

Comment on "Nurse-led postoperative telemonitoring program following outpatient urethroplasty: a pilot study".

World journal of urology·2026
See all related articles

Tolterodine is an effective anticholinergic medication for overactive bladders, offering a favorable side-effect profile compared to oxybutynin. Its efficacy in reducing symptoms and improving bladder capacity makes it a preferred treatment choice for diverse patient groups.

Area of Science:

  • Pharmacology
  • Urology

Background:

  • Detrusor instability and overactive bladder (OAB) are common conditions.
  • Anticholinergic medications are a primary treatment for OAB symptoms.

Purpose of the Study:

  • To evaluate the efficacy and safety of tolterodine for treating overactive bladder.
  • To compare tolterodine's effect-to-side-effect ratio with existing treatments like oxybutynin.

Main Methods:

  • Review of clinical studies on tolterodine's efficacy in OAB patients.
  • Assessment of symptom reduction (urgency, incontinence, frequency) and functional bladder volume increase.
  • Comparative analysis of side effect profiles.

Main Results:

  • Tolterodine effectively reduces OAB symptoms and increases bladder capacity.

Related Experiment Videos

  • It demonstrates a favorable effect-to-side-effect ratio, comparable to oxybutynin.
  • Clinical effectiveness is consistent across various patient demographics, including elderly and those with renal/hepatic insufficiency.

    • Conclusions:

    • Tolterodine is a suitable first-line treatment for overactive bladder.
    • Its favorable safety and efficacy profile supports its use in a broad range of patients.
    • An extended-release formulation may enhance patient compliance.